Microdosing: What the Science Actually Says About LSD Microdosing
The conversation around microdose LSD has exploded over the past decade — and not just in Silicon Valley circles. Researchers, clinicians, and curious individuals worldwide are asking the same question: does taking a fraction of a psychedelic dose actually do anything meaningful, or is it elaborate placebo? The honest answer, based on the latest controlled research, is nuanced — and worth understanding clearly before drawing conclusions.
What Is LSD Microdosing?
Microdosing LSD refers to the practice of taking sub-perceptual doses of lysergic acid diethylamide — typically between 5 and 20 micrograms (µg) — on a regular, scheduled basis. These doses sit well below the threshold needed to produce hallucinations or significantly altered states of consciousness. The goal, at least in theory, is to capture subtle benefits in mood, focus, and creativity without any of the psychedelic experience associated with a full dose.
To put it in perspective: a recreational dose of LSD typically ranges from 75 to 150 µg. An LSD microdose is roughly 5 to 15% of that. You’re not tripping. You’re not even close. Most people report feeling only slightly more alert or open — if they notice anything at all.
Common Microdosing Protocols
The most widely used scheduling approaches among people who microdose, based on observational survey data, include:
- The Fadiman Protocol: one day on, two days off — developed by psychedelic researcher Dr. James Fadiman
- The Stamets Protocol (adapted for LSD): four days on, three days off
- Every other day dosing
- Weekdays only, with weekends off
Most people who microdose do so for periods ranging from a few weeks to two years, according to a 2019 review of community microdosers. About half create their own individualized protocol based on personal response and lifestyle.
What Does the Research Actually Show?
This is where things get genuinely interesting — and more complicated than popular media tends to suggest. LSD microdosing has now been studied in over 19 placebo-controlled trials, and the findings paint a mixed but scientifically meaningful picture.
Neural and Biological Effects
Neuroimaging studies have found consistent evidence that lsd microdosing produces measurable changes in brain activity. Research published in peer-reviewed journals shows that low doses of LSD reduce resting-state activity in the default mode network (DMN) — the brain region associated with self-referential thought and rumination. Increased neural complexity and changes in inhibitory feedforward responses have also been documented, patterns consistent with enhanced neural plasticity.
One fMRI study found that an LSD microdose led to changes in neural connectivity across the amygdala and cerebellum — regions implicated in emotional processing and depression. These aren’t trivial findings. They suggest the drug is doing something biologically real, even at sub-perceptual doses.
Mood, Cognition, and Subjective Experience
Subjective reports from people who microdose consistently describe feelings of being more productive, happier, and positively under the influence — even when those ratings don’t always translate to measurable cognitive improvements on standardized tests.
A notable 2023 randomized controlled trial based out of New Zealand gave healthy male volunteers either 10 µg of LSD or a placebo every three days for six weeks, with most doses self-administered at home. The researchers found that microdosing produced transient mood-elevating effects, but did not produce lasting improvements to overall mood or cognition in healthy adults. Anxiety was the most significant adverse event, causing four participants to withdraw.
Critically, a separate analysis of participants who scored higher on baseline depressive symptoms found improvements in depression and mood both immediately after an LSD microdose and 48 hours later. This is an important nuance — ceiling effects may explain why healthy populations show limited measurable benefit. The drug may have more to offer people who are already struggling.
Reported Benefits of Microdosing LSD
Across observational surveys and self-report data — which represent a different picture than controlled trials — people who microdose LSD commonly report:
- Improved mood and emotional resilience
- Enhanced focus and ability to enter creative flow states
- Reduced symptoms of depression and anxiety (particularly in those with existing symptoms)
- Greater sense of presence and mindfulness
- Improved social connection and empathy
- Reduction in addictive behaviors (anecdotally reported; not yet clinically confirmed)
It’s worth being honest here: observational studies consistently report more benefits than controlled experimental trials. Part of this gap may be explained by the placebo effect and participant expectations. But researchers also acknowledge that laboratory settings may artificially suppress results that occur more naturally when people microdose in their own environments during daily life.
Risks and Considerations
Microdosing LSD is not without real risks, and anyone approaching it should understand them clearly. The safety profile from controlled studies in healthy adults is generally favorable — no serious adverse effects have been documented in clinical settings. However, several concerns remain:
- Anxiety: The most consistently reported adverse effect, particularly in people prone to anxiety or under high levels of life stress
- Cardiovascular concerns: Some studies recorded increases in blood pressure and heart rate at doses of 10-20 µg
- Tolerance: LSD builds tolerance quickly. University of Chicago research found that participants who microdosed repeatedly showed diminishing effects over time — interpreted as a positive safety signal, but also a practical consideration for anyone hoping to maintain consistent results
- Cardiac health: Long-term chronic use of serotonin 5-HT2B receptor agonists — which LSD activates — may theoretically carry cardiac risks. No long-term safety data currently exists
- Legal status: LSD remains a Schedule I controlled substance in the United States and is illegal in most countries. This carries legal risk regardless of intent or dose
LSD Microdosing vs. Psilocybin Microdosing
LSD and psilocybin are the two most studied substances in the microdosing literature. Both act primarily on serotonin 5-HT2A receptors, but they differ in duration, onset, and subjective character. An LSD microdose lasts 8 to 12 hours compared to psilocybin’s 4 to 6 hours — a practical difference that affects scheduling, particularly for working professionals.
From a research standpoint, the neurobiological findings are broadly consistent between the two. Both reduce DMN activity and increase neural complexity. However, the two substances have different chemical profiles and secondary receptor targets, meaning the effects are not fully interchangeable. People who microdose often report LSD as feeling more stimulating and cognitive, while psilocybin feels more emotional and introspective.
According to a 2025 RAND survey — the first nationally representative probability-based study of its kind — an estimated 10 million U.S. adults microdosed psilocybin, LSD, or MDMA in 2025, reflecting just how mainstream this practice has become despite its legal status.
Conclusion & Actionable Takeaways
LSD microdosing sits at a genuinely interesting intersection of neuroscience, personal experimentation, and evolving cultural norms. The science is real but incomplete. The biology is measurable but the clinical benefits remain unproven for healthy individuals. And the legal landscape hasn’t caught up with the research.
Here’s what you should take away from the current evidence:
- Microdosing LSD produces measurable neurobiological changes — this is no longer in question
- Controlled trials in healthy adults show limited lasting cognitive or mood benefits, but people with existing depression or anxiety may see more meaningful effects
- Anxiety is the most significant known risk; those with anxiety-prone temperaments should approach with caution
- Tolerance builds quickly, meaning consistent daily use is counterproductive — spacing doses out is both more effective and safer
- The gap between what people report in surveys and what shows up in labs likely reflects both placebo effects and the limitations of laboratory settings
- No long-term safety data exists — chronic use requires caution until more research is available
- Always consult a qualified healthcare professional before experimenting with any psychedelic substance, and understand the legal risks in your jurisdiction
The science of microdosing LSD is still young. What it has already shown is enough to take seriously — and enough to approach with clear-eyed caution rather than either uncritical enthusiasm or reflexive dismissal.
About the Author
Dr. Elaine Marsh
PhD, Neuropharmacology | Research Associate, Johns Hopkins Center for Psychedelic and Consciousness Research (former)
Dr. Marsh has spent over 12 years studying the pharmacology of serotonergic compounds and their effects on cognition and mental health. Her work has been published in Psychopharmacology, Neuropsychobiology, and the Journal of Psychedelic Studies. She advocates for rigorous, evidence-based discourse around psychedelic substances and harm reduction education.
Disclaimer: This article is intended for educational and informational purposes only. LSD is a Schedule I controlled substance in the United States and is illegal in many jurisdictions. Nothing in this article constitutes medical or legal advice. Always consult a licensed healthcare professional.
references
Szigeti B, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife.